Holen Sie sich die Stockscreener-App
12.89
6.25%
-0.86
Handel nachbörslich:
13.14
0.25
+1.94%
Schlusskurs vom Vortag:
$13.75
Offen:
$13.74
24-Stunden-Volumen:
332.03K
Relative Volume:
1.80
Marktkapitalisierung:
$439.47M
Einnahmen:
$99.53M
Nettoeinkommen (Verlust:
$-21.57M
KGV:
-19.87
EPS:
-0.6488
Netto-Cashflow:
$-9.84M
1W Leistung:
-12.96%
1M Leistung:
-18.88%
6M Leistung:
-14.81%
1J Leistung:
+51.47%
1-Tages-Spanne:
$12.66
$13.74
1-Wochen-Bereich:
$12.66
$15.83
52-Wochen-Spanne:
$7.5625
$19.60
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
12.89 | 521.63M | 99.53M | -21.57M | -9.84M | -0.6488 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
Orbimed Advisors LLC Decreases Holdings in NeuroPace, Inc. $NPCE - MarketBeat
Neuropace Inc (NPCE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NeuroPace, Inc. $NPCE Shares Acquired by First Light Asset Management LLC - MarketBeat
NPCE|Neuropace Inc|Price:14.810|Chg%:+0.130 - TradingKey
Neuropace Inc (NPCE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuropace Inc (NPCE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neuropace Inc (NPCE) Balance Sheet - TradingKey
Neuropace Inc (NPCE) Valuation: PE, PB & Fair Value Analysis - TradingKey
NeuroPace Inc introduces real-time solution to help restore everyday independence - Traders Union
Neuropace Inc (NPCE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NPCE|Neuropace Inc|Price:15.705|Chg%:+0.405 - TradingKey
Neuropace Inc (NPCE) Income Statement - TradingKey
NeuroPace Inc: Intermountain Health completes 100th RNS System implant for epilepsy patients - Traders Union
Neuropace Inc (NPCE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mizuho Securities Initiates NeuroPace(NPCE.US) With Buy Rating, Announces Target Price $22 - Moomoo
Mizuho Begins Coverage on NeuroPace (NASDAQ:NPCE) - MarketBeat
NEUROPACE INC : MIZUHO INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $22 - Bitget
Mizuho Securities Initiates Coverage on NeuroPace With Outperform Rating, $22 Price Target - marketscreener.com
Mizuho initiates NeuroPace stock coverage with outperform rating - Investing.com
NeuroPace Inc study reports landmark six month seizure reduction for RNS System patients - Traders Union
Neuropace, Inc. (NPCE) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
NeuroPace (NPCE) Proxy filing Summary - Quartr
(NPCE) Volatility Zones as Tactical Triggers - Stock Traders Daily
NeuroPace (NPCE) Stock Forum and Discussion - Moomoo
Here's why you should retain NeuroPace stock in your portfolio for now - MSN
NeuroPace (NPCE) 25th Annual Needham Virtual Healthcare Conference Summary - Quartr
Neuropace (NPCE) Holds Steady Near Resistance as Trading Volume Remains ModerateValue Area High - dars.gov.et
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now - Yahoo Finance
NeuroPace (NASDAQ:NPCE) Shares Down 5.8%What's Next? - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
NeuroPace (NASDAQ:NPCE) Stock Price Up 1.1%What's Next? - MarketBeat
NeuroPace Inc offers free webinar on RNS System for epilepsy patients - Traders Union
At US$17.80, Is It Time To Put NeuroPace, Inc. (NASDAQ:NPCE) On Your Watch List? - simplywall.st
DHR Health pioneers responsive neurostimulation therapy with NeuroPace Inc RNS System in Texas - Traders Union
Neuropace Inc. (NPCE) Q1 2026 Earnings: EPS Surpasses Estimates, Shares GainInvestor Earnings Call - dars.gov.et
Neuropace Inc. (NPCE) Q1 2026 Earnings: EPS Beats Estimates as Loss Narrows, Stock Rises 2.35%Trough Earnings Signal - dars.gov.et
Wall Street analysts see a 41.29% upside in NeuroPace (NPCE): Can the stock really move this high? - MSN
Price to earnings forward of Neuropace, Inc. – NASDAQ:NPCE - TradingView
NPCENeuroPace Inc Website Traffic and Mobile Apps Usage - Finviz
Neuropace Inc. (NPCE) Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesBasic EPS Analysis - dars.gov.et
NeuroPace | 4: Statement of changes in beneficial ownership of securities-Director Fischer Frank M - Moomoo
NeuroPace Inc patients see 62 percent median seizure reduction at six months in largest FDA-reviewed study - Traders Union
Price-Driven Insight from (NPCE) for Rule-Based Strategy - Stock Traders Daily
FDA Approves NeuroPace AI Driven Feature For Epilepsy Care - HarianBasis.co
NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™ - Insider Monkey
NeuroPace, Inc. Actuals & Estimates (NASDAQ:NPCE) - TradingView
NeuroPace (NPCE) CMO has shares withheld to cover RSU tax bill - Stock Titan
NPCE Forecast — Price Target — Prediction for 2027 - TradingView
Neuropace Inc. (NPCE) Q1 2026 Earnings: Narrowed Loss Beats Estimates, Shares Edge HigherReturn On Assets - dars.gov.et
Neuropace Inc (NPCE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neuropace Inc. (NPCE) Gains on Rising Volume: Support Holds Above $15Fibonacci Extension - dars.gov.et
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.04%
11.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):